News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer.
Cell and gene therapies have been making the news this week, as we launch our very own guide to global innovation in CGT with the Winter issue of DDW, as well as an exciting new virtual event on the same topic.
The top stories:
Gene therapy for cystic fibrosis receives EC orphan drug designation
The European Commission has granted orphan designation for Krystal Biotech’s KB407 for the treatment of cystic fibrosis (CF).
EMA prioritises AAV gene therapy for Krabbe disease
The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge Biologic’s adeno-associated virus (AAV) drug candidate for treating patients with Krabbe disease.
Partners to commercialise CAR-T product in China
CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen’s BCMA CAR-T product CT053 in mainland China.
$35 million to advance AI-driven RNA structure platform
Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round.
$5 million raised towards gene therapies for muscular diseases
Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne.
